Tag - FDAs

Comparative analysis of adverse events associated with CDK4/6 inhibitors based on FDA’s adverse event reporting system: a case control pharmacovigilance study | BMC Pharmacology and Toxicology

August 10, 2024

As a result of the widespread use of CDK4/6 inhibitors and increasing awareness among healthcare providers, the number of AEs reported has escalated over the...